Recent advances are pushing the boundaries of cell and gene therapy development and manufacturing. Efficient nucleic acid quantitation technologies like Countable PCR improve accuracy for gene therapy quality control. Companies such as Biointron offer scalable bispecific antibody production services to accelerate research. Novel multiplex diagnostic panels enable rapid pathogen identification. Automated, closed-system manufacturing platforms enhance reproducibility, reduce contamination, and streamline clinical and commercial therapeutics development.